TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), presented three posters at the American College of Allergy, Asthma and Immunology from November 9th -15th in Philadelphia, PA. These posters discussed findings from surveys of U.S. and EU otolaryngologists (ENTs), and U.S. allergists on the fungal etiology associated with chronic sinusitis (CS), especially in patients refractory to surgery, and the overall need for effective pharmacotherapies in CS patients in general.
